Exelixis | EXEL - Ebit



金融业
股票价格
USD
资产
USD 2.59B
现金及等价物
USD 226.15M
销售成本
USD 19.95M
流动资产
USD 1.21B
流动负债
USD 370.98M
债务
USD 169.54M
EBIT
USD 251.34M
EBITDA
USD 258.29M
员工
1.15K
EPS每股收益
USD 0.87
股本和储备
USD 1.94B
销售毛利
USD 590.86M
债务利息支出
USD 23.4M
利息收入
USD 16.13M
市值
USD 14.17B
净收入
USD 210.47M
营业费用
USD 359.47M
营业利润
USD 251.34M
普通股股本
USD 253.7M
PE价格收益
13.91
税前利润
USD 267.69M
销售收入
USD 610.8M
销售和管理费用
USD 139.6M
股票
USD 26.61M
贸易债权人
USD 24.15M
应收帐款人
USD 328.95M


Ebit 更改 日
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Akebia Therapeutics USD -5.45M 9.4M 2025-12
Amgen USD 3.83B 130M 2026-03
AstraZeneca USD 7.11B 4.14B 2026-03
Bayer EUR 3.53B 2.42B 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Bristol-Myers Squibb USD 3.56B 90M 2026-03
Cytokinetics USD -181.23M 2.86M 2026-03
Eisai JPY -10.31B 30.35B 2026-03
Eli Lilly USD 9.78B 792M 2026-03
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Exelixis USD 251.34M 15.43M 2026-03
Genmab DKK 260M 199M 2025-12
Glaxosmithkline GBP 2.3B 1.46B 2025-12
Incyte USD 344.17M 39.71M 2026-03
Ionis Pharmaceuticals USD -118M 97M 2026-03
MacroGenics USD -12.1M 32.26M 2025-12
Merck USD -1.88B 8.12B 2026-03
Moderna USD -1.39B 531M 2026-03
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
Novartis USD 4.18B 118M 2026-03
Pfizer USD 4.99B 340M 2026-03
Puma Biotechnology USD -2.2M 11.41M 2024-06
Sanofi EUR 3.74B 2.23B 2025-09
Takeda JPY -13.62B 271.11B 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Xencor USD -77.86M 24.23M 2026-03